Cullen Capital Management LLC Grows Position in Baxter International Inc. $BAX

Cullen Capital Management LLC increased its stake in shares of Baxter International Inc. (NYSE:BAX) by 10.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,651,542 shares of the medical instruments supplier’s stock after acquiring an additional 155,415 shares during the quarter. Cullen Capital Management LLC owned about 0.32% of Baxter International worth $50,009,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of BAX. Dodge & Cox boosted its holdings in shares of Baxter International by 2.1% during the 1st quarter. Dodge & Cox now owns 51,458,925 shares of the medical instruments supplier’s stock valued at $1,761,439,000 after purchasing an additional 1,081,631 shares during the last quarter. Geode Capital Management LLC boosted its stake in Baxter International by 2.6% during the second quarter. Geode Capital Management LLC now owns 12,882,960 shares of the medical instruments supplier’s stock valued at $388,416,000 after buying an additional 326,652 shares during the last quarter. Parkwood LLC purchased a new position in Baxter International during the 2nd quarter valued at approximately $9,459,000. Russell Investments Group Ltd. increased its stake in Baxter International by 13.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,900,828 shares of the medical instruments supplier’s stock worth $57,568,000 after acquiring an additional 224,804 shares during the last quarter. Finally, Park National Corp OH increased its stake in Baxter International by 2,691.4% in the 2nd quarter. Park National Corp OH now owns 219,512 shares of the medical instruments supplier’s stock worth $6,647,000 after acquiring an additional 211,648 shares during the last quarter. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Price Performance

BAX stock opened at $19.17 on Monday. The stock has a market cap of $9.86 billion, a PE ratio of -29.05, a P/E/G ratio of 1.10 and a beta of 0.61. Baxter International Inc. has a 12 month low of $17.40 and a 12 month high of $37.74. The company has a 50-day moving average price of $19.98 and a 200 day moving average price of $24.29. The company has a current ratio of 1.84, a quick ratio of 1.18 and a debt-to-equity ratio of 1.21.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.09. Baxter International had a negative net margin of 3.09% and a positive return on equity of 17.38%. The company had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.88 billion. During the same period in the prior year, the company posted $0.80 EPS. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS and its FY 2025 guidance at 2.350-2.400 EPS. Equities research analysts anticipate that Baxter International Inc. will post 2.48 earnings per share for the current year.

Baxter International Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Friday, November 28th will be issued a dividend of $0.01 per share. The ex-dividend date is Friday, November 28th. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. Baxter International’s payout ratio is presently -6.06%.

Wall Street Analysts Forecast Growth

BAX has been the subject of a number of recent research reports. Zacks Research raised shares of Baxter International from a “strong sell” rating to a “hold” rating in a report on Monday, December 1st. Argus lowered shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Friday, October 31st. Morgan Stanley reduced their target price on shares of Baxter International from $19.00 to $15.00 and set an “underweight” rating on the stock in a report on Tuesday, December 2nd. Stifel Nicolaus lowered their price target on shares of Baxter International from $25.00 to $22.00 in a report on Friday, October 31st. Finally, Evercore ISI dropped their price target on Baxter International from $31.00 to $24.00 in a research report on Thursday, October 30th. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Baxter International has an average rating of “Hold” and an average price target of $22.00.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.